News for Tetra Bio-Pharma Inc. (TBPMF)

This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2023 Benzinga.com. Benzinga does not provide investment advice....

This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2023 Benzinga.com. Benzinga does not provide investment advice....

GAINERS: LOSERS: This article was generated by Benzinga's automated content engine and reviewed by an editor.

This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2023 Benzinga.com. Benzinga does not provide investment advice....

This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2023 Benzinga.com. Benzinga does not provide investment advice....

This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2023 Benzinga.com. Benzinga does not provide investment advice....

This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2023 Benzinga.com. Benzinga does not provide investment advice....

This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2023 Benzinga.com. Benzinga does not provide investment advice....

This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2023 Benzinga.com. Benzinga does not provide investment advice....

This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2023 Benzinga.com. Benzinga does not provide investment advice....

Tetra Bio-Pharma Inc. Announces a Delay in Filing 2022 Annual Financial Statements…

MONTREAL, Feb. 10, 2023 /PRNewswire/ - Tetra Bio-Pharma Inc.   , a leader in cannabinoid-derived drug discovery and development, today announced that its common shares began trading on the OTC... | February 10, 2023

/PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and...

Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1), announced results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), sepsis, and COVID-19 through PREPAiRE, an AI

MONTREAL, Nov. 18, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development is providing its shareholders with a regulatory status update on... | November 18, 2022

/PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and...

Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1), has closed the second tranche of its financing arrangement with Global Corporate Finance Opportunities 16, an investment vehicle advised by Alpha Blue Ocean, pursuant to the terms of an amended and

OTTAWA, ON, Oct. 27, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. , a leader in cannabinoid-based drug discovery and development, announced today that the Company has closed the second tranche of... | October 27, 2022

MANAGEMENT'S DISCUSSION TETRA BIO-PH RMAANDI C. ANALYSIS For the three and nine months ended August 31, 2022 ... | October 18, 2022